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Abstract 
A 28-year-old man with bilateral central serous chorioretinopathy (CSCR) and body 
weight gain was diagnosed with Cushing’s syndrome secondary to an adrenocortical 
adenoma. The patient had high levels of free cortisol and the tumor was confirmed by 
histopathology. After surgery, cortisol levels decreased and the CSCR spontaneously 
resolved. This case highlights the role of cortisol in the pathogenesis of CSCR. A 
diagnosis of endogenous Cushing’s syndrome should be considered in patients with 
CSCR as an initial symptom. 
 
Introduction 
Central serous chorioretinopathy (CSCR) is a relatively frequent ocular disorder 
characterized by the accumulation of subretinal fluid at the posterior pole, causing a 
circumscribed area of retinal detachment [1]. The detachment frequently involves the 
macular area, such that patients usually complain of metamorphopsia, micropsia, 
macropsia, or central scotoma. Visual acuity is often moderately decreased and, in most 
cases, the CSCR spontaneously resolves within a few months. The pathophysiology 
remains unclear [1–6]. Case Rep Ophthalmol 2011;2:327–332 
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Case Report 
A 28-year-old man presented at the Department of Ophthalmology, University Clinic Hospital of 
Valladolid, with a 3-month history of progressive bilateral vision loss, blurred vision, and 
metamorphopsia in both eyes. He denied any remarkable past medical history and concurrent systemic 
treatment; he also denied a history of abuse of tobacco, alcohol, or illegal drugs. 
His best-corrected visual acuity was 20/25 in the right eye and 20/40 in the left eye. Anterior segment 
examination was normal in both eyes. Fundus oculi evaluation revealed retinal pigmentary 
abnormalities in the macula of both eyes (fig. 1a, b). There was also a serous detachment of the 
neurosensory retina associated with a small retinal pigment epithelium (RPE) detachment in the left 
eye. The detachment was confirmed (fig. 1c, d) by optical coherence tomography (3D OCT-1000; 
Topcon, Tokyo, Japan). There was no evidence of intraocular inflammation, retinal holes, tears, or 
retinal choroidal neovascularization. 
Autofluorescence images (TRC-50EX, Imaginet 2000; Topcon) showed diffuse areas of increased 
autofluorescence and reduced intensity in the macular and peripapillary areas. Upon fluorescein 
angiography, there were multiple pinpoint areas of hyperfluorescence in the macula and peripapillary 
areas. There were also areas of independent leakage with a mottled appearance and low activity from 
early stages without later changes (fig. 2). The patient was diagnosed with CSCR. 
No specific treatment was prescribed for the CSCR, and 6 months later it remained unchanged. The 
patient’s best-corrected visual acuity and fundus oculi evaluation revealed minimal changes. However, 
he suffered progressive systemic changes, including a 10-kg increase in body weight, supraclavicular fat 
accumulation around the neck and face (moon face), dorsocervical fat pad (buffalo hump), purple 
striae, and thin skin (fig. 3a, b). A tentative diagnosis of hypercortisolism [7] was made, and the patient 
was sent to the Endocrinology Department of the University Clinic Hospital to confirm the diagnosis. 
His urinary free cortisol was 264.7 μg/24 h, confirming the tentative diagnosis of hypercortisolism. A 
low-dose (1 mg) dexamethasone suppression test was performed, revealing a mean cortisol level of 
19.94 μg/100 ml. A follow-up high-dose (8 mg) dexamethasone suppression test was performed, and a 
suppressed adrenocorticotropic hormone serum level assay value of <5 pg/ml confirmed the previous 
dexamethasone suppression test. These results suggested the possibility of adrenocorticotropic 
hormone-independent Cushing’s syndrome. Subsequently, an abdominal CT scan without contrast was 
performed and revealed the presence of a left adrenal oval-shaped mass with irregular enhancement (fig. 
3c, d). Plasma aldosterone concentration, plasma renin activity, and 24-hour urinary catecholamines 
were negative. 
Following these tests, the patient was treated with ketoconazole and steroid replacement therapy 
before consulting surgeons performed a laparoscopic left adrenalectomy. Histopathological examination 
revealed the presence of an adrenocortical adenoma. Hydrocortisone was administered after surgery to 
restore the physiologic hypothalamic-pituitary-adrenal axis. 
One month after surgery, the patient’s best-corrected visual acuity improved to 20/20 in both eyes. 
The fundus examination showed only RPE abnormalities, but there were no signs of CSCR. Optical 
coherence tomography images confirmed that the RPE detachment had resolved (fig. 1e, f). 
Discussion 
Psychological stress, hormonal changes in pregnancy, and glucocorticoid treatments 
[1–4] can all contribute to the development of CSCR, though the influence each of these 
circumstances has on CSCR is not well understood. Corticosteroids may inhibit collagen 
synthesis and increase choriocapillaris fragility and permeability by altering ion transport 
across the RPE [5]. Other proposed mechanisms of corticosteroid-dependent increases in 
capillary fragility and permeability include inhibition of fibroblast proliferation, alteration 
of leukocyte migration, and release of proteolytic enzymes [4, 5]. Corticosteroids could Case Rep Ophthalmol 2011;2:327–332 
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also cause local ischemia by reducing choroidal fibrinolysis, leading to choroidal 
endothelial and RPE injury with consequent increased permeability [5]. 
There are few studies relating CSCR to endocrinological dysfunction characterized by 
hypercortisolism. CSCR has been reported in only 5% of patients with Cushing’s 
syndrome, all of whom had a pituitary adenoma [6]. In each of these cases, the CSCR 
occurred during the period of active, untreated disease while plasma cortisol levels were 
high. 
However, 2 new cases of CSCR have been reported as a result of hypercortisolism due 
to an adrenocortical adenoma [8]. Because both CSCR and adrenocortical adenomas are 
not very common diseases, a coincidental association is highly improbable. Furthermore, 
considering the resolution of CSCR in our patient without any systemic treatment 
following the adrenocortical adenoma resection, we suggest that hypercortisolism could 
be an important risk factor for CSCR. Our case underscores the importance of 
considering the possibility of a diagnosis of endogenous Cushing’s syndrome in patients 
with CSCR as an initial symptom. 
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Fig. 1. Fundus color images of the right (a) and left (b) eye showing retinal pigmentary abnormalities in 
the macula and a serous retinal detachment in the left eye (white circumscribed area). Optical coherence 
tomography of the right (OD) (c) and left (OS) (d) eye showed chronic changes in the RPE layer (white 
arrows). The serous detachment of the neurosensory retina in the OS (d) was also evident. Optical 
coherence tomography images showed chronic changes in the RPE layer (e, f), and confirmed that the 
RPE detachment had resolved in the OS (f). 
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Fig. 2. Fluorescein angiography (FA) showed multiple pinpoint areas of hyperfluorescence in the 
macula and peripapillary areas. There was also independent leakage in areas with a mottled appearance 
and low activity from early stages. 
 
 
 
Fig. 3. The patient exhibited clinical features of endogenous Cushing’s syndrome: moon face (a); 
overweight with purple striae on the skin (b). Abdominal CT scans revealed a left adrenal oval-shaped 
mass (red X) in coronal (c) and axial images (d). 
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